Biologics make higher rates of clinical response and remission possible, including anti-TNF drugs, anti-integrin medications, and interleukin-12/23 inhibitors, which have revolutionized the treatment of moderate to severe IBD. This evidence concerns the gene TNF and inflammatory bowel disease.